Invitae (NVTA) Is Invitae A Buy?

Follow Us on Stocktwits

Invitae (NVTA) announced preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year.

Invitae Corp. (NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2019 results, driving strong growth in volume and revenues. The company signals continued momentum going into 2020.

Invitae Corp. accessioned more than 482,000 samples and generated approximately $216 million in revenue in 2019. The company issues 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue. This reflects a more than 50% annual growth in both gross volume and revenue.

Is Invitae A Buy?

Invitae Corp. (NYSE: NVTA) is a unique company well positioned to tackle the use of genetic information across all stages of life—from preconception through adult diagnostics. Invitae has acquired three companies that are intended to further enhance Invitae’s clinical variant interpretation capabilities. This will reduce the cost of testing and provide exceptional customer workflows and patient support. The company presented and published clinical research and launched Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch. This platform provides a better understanding of the genetic causes of disease, with the first study in cardiovascular disease.

Cathie Woods, ARK Invest CEO said in a statement on CNBC Television that ”Invitae is one of the most important molecular diagnostic companies out there riding down the cost curve of DNA sequencing.”

Invitae Price Target

Institutional Ownership

Invitae Corp. (NVTA) has an institutional ownership of (89.54%). 364 institutional investors and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 90,567,880 shares. Largest shareholders include Baker Brothers Advisors LP, ARK Investment Management LLC, Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., BlackRock Inc., Gilder Gagnon Howe & Co Llc, State Street Corp, Vanguard Group Inc, Alliancebernstein L.p., and Casdin Capital, LLC.

About Invitae

Invitae Corp. (NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at invitae.com.

How much does Invitae cost?

Genetic testing should be affordable and accessible to anyone who could benefit. To make proactive testing affordable to patients, Invitae offers the Cancer Screen and Cardio Screen for $250 and the Genetic Health Screen for $350. Payment must be made by credit card before a report can be released.

Is Invitae a good company?

Invitae is the best company I’ve ever worked for and it’s not close. Invitae has an incredibly strong mission that attracts people who care deeply about making a positive change in the world by making healthcare better and more affordable for real people, every day through genetic testing.

What is Invitae genetic testing?

Invitae offers three tests that provide information on well-established genetic risk factors for developing hereditary cancers, cardiovascular conditions and other medically important disorders.

Be the first to comment

Leave a Reply

Your email address will not be published.


*